Indivior Pharmaceuticals (INDV) Non-Current Assets (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Non-Current Assets of $530.0 million for Q1 2026, up 7.72% year-over-year from $492.0 million in Q1 2025, and down 3.46% quarter-over-quarter from $549.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Non-Current Assets (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Non-Current Assets history runs 6 years deep, the most recent figure standing at $530.0 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 7.72% year-over-year to $530.0 million; the TTM figure through Mar 2026 stood at $2.1 billion (up 830.04% YoY), while the FY2025 annual figure was $549.0 million, up 12.27% from the prior year.
- Non-Current Assets for Q1 2026 stood at $530.0 million, down from $549.0 million in the prior quarter.
- The five-year high for Non-Current Assets was $549.0 million in Q4 2025, with the low at -$1.3 billion in Q4 2022.
- The 5-year median for Non-Current Assets is $497.5 million (2023), against an average of $287.1 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets soared 139.79% in 2023, then dropped 2.4% in 2024.
- Indivior Pharmaceuticals' Non-Current Assets stood at -$1.3 billion in 2022, then surged by 139.79% to $501.0 million in 2023, then declined by 2.4% to $489.0 million in 2024, then advanced by 12.27% to $549.0 million in 2025, then fell by 3.46% to $530.0 million in 2026.
- Business Quant data shows INDV's Non-Current Assets at $530.0 million in Q1 2026, $549.0 million in Q4 2025, and $494.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Indivior Pharmaceuticals | 4.56 Bn | 4.34 Bn | 294.00 Mn | 508.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 508.00 Mn |
| Mar 31, 2026 | 530.00 Mn |
| Dec 31, 2025 | 549.00 Mn |
| Sep 30, 2025 | 494.00 Mn |
| Jun 30, 2025 | 501.00 Mn |
| Mar 31, 2025 | 492.00 Mn |
| Dec 31, 2024 | 489.00 Mn |
| Dec 31, 2023 | 501.00 Mn |
| Dec 31, 2022 | -1.26 Bn |
| Dec 31, 2021 | -1.44 Bn |